Extended Data Fig. 3: Preconditioning regimens for lymphodepletion and cDC1 expansion following OT-I FL therapy. | Nature Immunology

Extended Data Fig. 3: Preconditioning regimens for lymphodepletion and cDC1 expansion following OT-I FL therapy.

From: Adoptive cellular therapy with T cells expressing the dendritic cell growth factor Flt3L drives epitope spreading and antitumor immunity

Extended Data Fig. 3: Preconditioning regimens for lymphodepletion and cDC1 expansion following OT-I FL therapy.The alternative text for this image may have been generated using AI.

a, Analysis of splenic immune cell subsets 2 days after total body irradiation (TBI), representative of one of two independent experiments with similar results. b, Fold change of immune cell subsets normalized to control non-irradiated mice. c, Comparison of splenic immune cell subsets after preconditioning with titrated doses of TBI or cyclophosphamide (CP). d, Fold change of immune cell subsets after 0.5 Gy TBI or 50 mg/kg CP normalized to control mice. e, hHer2 mice were irradiated at indicated doses and subcutaneously inoculated with 5 × 105 Flt3L expressing 24JK-Her2 cells (n = 6 mice/group), from of one of two independent experiments (2-way ANOVA). f–g, Absolute numbers of BM pre-cDC, pre-cDC1 and pre-cDC2 per femur, and splenic cDC1 and cDC2 populations 7 days post adoptive transfer, after preconditioning with 0.5 Gy TBI or 50 mg/kg CP. Bars represent mean ± SEM, a, f, g 1-way ANOVA, symbols represent individual mice.

Source data

Back to article page